Rani Therapeutics Holdings, Inc. - Class A Common Stock (RANI)
1.4200
-0.1000 (-6.58%)
Rani Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing innovative oral therapies for the delivery of biologics, such as peptides and proteins, which traditionally require injection for administration
The company’s proprietary RaniPill platform utilizes a novel approach to encapsulate and deliver these treatments orally, aiming to enhance patient compliance and accessibility in the administration of complex medications. By combining advanced engineering with pharmaceutical expertise, Rani Therapeutics is exploring solutions that could revolutionize the landscape of therapeutic delivery, making it more patient-friendly.
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
